soul trial oral semaglutide cardiovascular outcomes results 2025 2024 nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results SOUL: Oral Semaglutide Cuts CV
USD29.32
USD67.32
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
![Ozempic and Wegovy increase risk of thyroid cancer. “Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio [HR] 1.58, 95% CI 1.27-1.95)](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3139055092816828788)
